Glaxo Group Limited

Glaxosmithkline Istrazivacki Centar Zagreb D.o.o.

Fidelta D.o.o.

Selvita D.o.o.

Goran Kragol

Antun Hutinec

Zorica Marusic Istuk

Gordon Saxty

Milan Mesic

Dijana Pesic

Sulejman Alihodzic

Vanja Vela

Ivaylo Jivkov Elenkov

Martina Bosnar

Renata Rupcic

Ivana Ozimec Landek

Maja Matanovic Skugor

Kristina Butkovic

Mirjana Bukvic

Gorjana Lazarevski

Boska Hrvacic

Dinko Ziher

Visnja Poljak

Zorica Marusic-Istuk

Andrea Fajdetic

Ognjen Culic

Marko Duksi

Sanja Kostrun

Darko Filic

Caroline Jane Day

Nikola Marjanovic

Leanda Jane Kindon

Vesna Erakovic Haber

Vesna Erakovic

Marija Leljak

Marija Ribic

Dubravko Jelic

Julien Bruno Douillet

Vanesa Ivetic

Marija Tomaskovic

Berislav Bosnjak

Vesna Munic

The present invention relates to seco (opened ring) macrolide compounds, to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, to macrolide based macrocycles obtained from said seco macrolide compounds, to the process for preparation of macrolide based macrocycles, to the pharmaceutical compositions comprising macrolide based macrocycles, and to the use of macrolide based macrocycles as therapeutic agents.

Seco macrolide compounds

The compound 3'-N-demethyl-4&#x2033;-O-(2-diethylaminoethanoyl)-6-O-methyl-9a-aza-9a-homoerythromycin A, having the Formula (I): or a salt thereof, compositions comprising the compound, its use in the treatment of neutrophil dominated inflammatory diseases, and methods for its preparation.

Anti-infammatory macrolide

The present invention relates to novel semi-synthetic macrolides having anti-inflammatory activity. More particularly, the invention relates to 14- and 15-membered macrolides substituted at the 4&#x2033; position, to their pharmaceutically acceptable derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their activity and use in the treatment of inflammatory diseases and conditions in humans and animals, especially those diseases associated with excessive secretion of TNF-&#x3b1;, IL-1, IL-8, IL-2 or IL-5; and/or inhibitor of excessive lymphocyte proliferation; and/or excessive granulocyte degranulation.

Macrolides with anti-inflammatory activity

The present invention relates to novel semi-synthetic macrolides having anti-inflammatory activity. More particularly, the invention relates to 14- and 15-membered macrolides lacking cladinose sugar substituted at the C-3 position, to their pharmaceutically acceptable derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their activity and use in the treatment of inflammatory diseases and conditions in humans and animals, especially those diseases associated with excessive secretion of TNF-&#x3b1;, IL-1, IL-6, IL-8, IL-2 or IL-5; and/or inhibitor of excessive lymphocyte proliferation; and/or excessive granulocyte degranulation.

Decladinosyl-macrolides with anti-inflammatory activity

Growing community of inventors

Zagreb, Croatia

Goran Kragol